PHARMACEUTICAL MANUFACTURING
JTA Health invests and operates in the manufacturing and technology transfer of high-tech (NOT GENERIC) pharmaceutical products, including:
- Human Vaccines, Immuno-stimulant Supplements, and Probiotics (Preventive Strategies).
- Biosimilars, including Recombinant proteins, Stem cell-based therapy, Enzymes, Gene therapy, Immunotherapeutic, and Monoclonal antibodies (Therapeutic Strategies).
JTA HEALTH DESIRES TO OBTAIN THE LEADERSHIP OF:
The most effective
The most innovative
The most cost-affordable medications against all types of:
Cancers (e.g., Colorectal, Breast, Bladder, Prostate, Lung, Leukemia, Myeloma, Liver, Pancreas, etc.);
Neurological and Mental disorders (e.g., Alzheimer's, Parkinson's, Stroke, Spinal Cord Injury, Ataxia, Cerebral Aneurysm, depression, epilepsy, etc.);
Auto-immune diseases (e.g., Rheumatoid arthritis, Multiple sclerosis, Anemia, Myasthenia, Lupus erythematosus, Sjögren syndrome, etc.);
Infectious diseases including Bacterial (e.g., Tuberculosis, Leprosy, Diphtheria, Tetanus, Whooping Cough, Meningitis, Anthrax, Pneumococcal infections, Hemophilus, Cholera and Typhoid , etc.), Viral (e.g., Human Immunodeficiency Viruses “HIV”, Human Papilloma Virus “HPV”, Influenza, Zoster, Covid-19, Yellow fever, Smallpox, Measles-Mumps-Rubella “MMR” and Hepatitis, etc.), and Fungal Infections (Mycosis) (e.g., Athlete’s foot, Jock itch, Onychomycosis, Candidiasis and yeast infections, etc.);
Metabolic disorders (e.g., Diabetes, Obesity, Gaucher’s disease, PKU, hemochromatosis, etc.).
JTA Health finances every step of the pharmaceutical production process that is connected to Capital Expenditures (CAPEX) and Operational Expenditures (OPEX), such as:
- Factory construction and GMP (Good Manufacturing Practice) approved clean rooms and Quality Control laboratories;
- Supply all of pharmaceutical-grade machines and equipment;
- Technology Transfer and preparation of Secondary Seed bank, Working Reference and the Product Know-How, including: Plant designs, Documentation, Material Specifications, Analytical Methods, User Requirements Specification (URS), Validation, Stability protocols and Artworks;
- Engineering studies and required compliance to international GMP authorities [European GMP and US FDA (Food and Drug Administration)] as well as local NRA (National Regulatory Authorities) and MOH (Ministry of Health);
- OPEX of Year -1 to Year +1;
- Clinical Trials of FINISHED products;
- Costs of obtaining local GMP and training of technical and production staff;
- Costs for production of the 3 consecutive batches required for the regional registration of the products.
